ATS Corporation (ATS:CA) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate strong financial performance, with a solid order backlog and promising growth in segments like Life Sciences and Energy. Despite some uncertainties, management provided optimistic guidance, focusing on margin expansion and strategic initiatives. The stock is likely to experience a positive movement, considering the company's market cap and the absence of significant negative factors.
Key Financial Performance
Order Bookings $734 million, down 1.1% compared to Q2 last year. The decline was due to fewer large enterprise bookings in Life Sciences, partially offset by growth in other markets.
Revenues $729 million, up 18.9% year-over-year. This increase was driven by 12.6% organic growth, a 3.9% benefit from foreign exchange translation, and a 2.4% contribution from acquisitions.
Adjusted Earnings from Operations $79.1 million, a 40% increase from the prior year. This growth was primarily due to higher revenue volumes.
Gross Margin 29.9%, a 36 basis point increase compared to Q2 last year.
SG&A Expenses $134.5 million, a $14.5 million increase over the prior year. The rise was mainly due to incremental SG&A from acquired companies and FX translation impact.
Stock-Based Compensation Expense $4.3 million, excluding recovery related to forfeitures from the former CEO's departure and mark-to-market impact related to changes in share price.
Earnings Per Share (EPS) $0.45 on an adjusted basis.
Order Backlog Approximately $2.1 billion, providing good revenue visibility.
Cash Flows from Operating Activities $28 million in Q2.
Noncash Working Capital as a Percentage of Revenues 18.3%, with a target of 15% by the end of the fiscal year.
CapEx and Intangible Asset Investment $18.3 million in Q2, with a full-year expectation of $80 million to $100 million.
Net Debt to Adjusted EBITDA Ratio 3.4x, with progress made towards the target range of 2 to 3x.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Comecer Competence Center: Opened in Indianapolis to enhance service capabilities and faster response times for North American customers. Secured new wins in diagnostic and therapeutic projects for radiopharmaceutical production.
Illuminate Manufacturing Intelligence Platform: Further developed to support new deployments, integrate equipment, standardize data capture and analytics, and improve visibility across the installed base.
Life Sciences: Order backlog at $1.1 billion, driven by demand in radiopharma, auto-injectors, diagnostic wearables, and automated pharmacies. Positioned to support emerging applications for GLP-1 therapies.
Food and Beverage: Order backlog at $218 million, with customer wins in primary processing, sorting, and inspection. Focus on automation to enhance yield, quality, and energy efficiency.
Energy: Order backlog at $277 million, up 154% from last year, driven by nuclear refurbishment projects and new reactor builds, including small modular reactors.
Consumer Products: Stable funnel with ongoing programs in personal care, household goods packaging, and warehouse automation.
Adjusted Earnings: Increased by 40% to $79.1 million due to higher revenue volumes.
Restructuring Costs: Estimated at $15 million for the second half of fiscal year to realign cost structure and drive global operational efficiencies.
Working Capital Efficiency: Focus on reducing noncash working capital as a percentage of revenues to 15% by year-end.
M&A Activity: Active funnel with focus on aligning with long-term strategic priorities and integrating recent acquisitions for synergies.
Innovation Summit: Held to foster a unified innovation ecosystem, accelerate product development, and strengthen collaboration on emerging technologies.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Leadership Transition: The company is undergoing a leadership transition with an interim CEO and CFO, which could create strategic and operational uncertainties until a permanent CEO is appointed.
Government-Funded Customers: Government-funded customers in the lab research space are taking a more measured approach to capital investment due to changes in the U.S. funding environment, potentially impacting revenue from this segment.
Restructuring Costs: The company plans to incur approximately $15 million in restructuring costs in the latter half of the fiscal year, which could temporarily impact financial performance.
Geopolitical Tensions and Trade Considerations: Dynamic macroeconomic conditions, including geopolitical tensions and trade and tariff considerations, could pose risks to operations and profitability.
Leverage and Debt Management: The company’s net debt to adjusted EBITDA ratio is 3.4x, above its target range of 2 to 3x, indicating a need for continued focus on debt reduction.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Order Backlog: Order backlog of approximately $2.1 billion provides good revenue visibility. Life Sciences backlog is strong at $1.1 billion, with opportunities in radiopharma, auto-injectors, diagnostic wearables, and automated pharmacies. Energy backlog reached a record $277 million, driven by nuclear refurbishment projects and new reactor builds.
Revenue Expectations: Q3 revenues are expected to be in the range of $700 million to $740 million. Full-year revenue growth is expected to remain in the high single digits.
Adjusted Operating Margin: Adjusted operating margin improvement is expected on a full-year basis for fiscal '26.
Restructuring Costs: Restructuring costs of approximately $15 million are expected in the second half of fiscal '26, with a payback period of less than one year.
Capital Expenditures: Fiscal '26 CapEx and intangible investments are expected to be within the range of $80 million to $100 million.
Leverage: Net debt to adjusted EBITDA ratio is expected to reduce to within the target range of 2 to 3x by the end of fiscal '26.
Market Trends and Opportunities: Momentum in radiopharma is supported by investments in production capacity and new therapeutics. Nuclear energy demand is growing, supported by clean energy policies and data center needs. Food and Beverage automation investments focus on yield, quality, and energy efficiency.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What gives you confidence that the slowdown in bookings momentum is just normal lumpiness and not something more?
A:Ryan McLeod explained that the book-to-bill ratio is healthy at 1.12, and the backlog is up about 14% year-over-year. He highlighted healthy funnel activity across vertical markets such as life sciences, food, consumer, transportation, and energy. He also mentioned growth opportunities in nuclear energy, including refurbishment, decommissioning, and new builds.
Q:How did the services business perform in the second quarter, and are you planning to replace Simon Roberts?
A:Anne Cybulsk stated that the services business performed strongly in the quarter and year-to-date, with recurring revenue and strategic importance to growth plans. Ryan McLeod confirmed that Simon Roberts has taken a leadership role in Packaging and FoodTech, and they plan to replace his previous role.
Q:What is driving the margin trajectory for the back half of the year and fiscal '27?
A:Anne Cybulsk stated that margin expansion remains a focus, supported by growth and restructuring initiatives. Cost savings from restructuring will be reinvested in higher growth areas and innovation. Multiple levers are available to drive margin improvement.
Q:What is the approach to inorganic growth and leverage management?
A:Ryan McLeod mentioned that they are actively reviewing opportunities while focusing on reducing leverage to provide more flexibility. Equity remains an option for the right deal, and the U.S. listing makes shares more attractive for M&A. They aim to balance deleveraging with market activity.
Q:What is the general outlook for the healthcare space and opportunities in that sector?
A:Ryan McLeod highlighted healthy funnel activity in auto-injectors, radiopharma, and new drug delivery technologies. He mentioned growth in multi-dose auto-injectors and radiopharma projects moving from R&D to commercial manufacturing. The Comecer competence center in Indianapolis supports regional growth.
Q:What is the timeline for nuclear backlog revenue conversion?
A:Anne Cybulsk explained that most nuclear backlog is related to reactor refurbishment, expected to continue for 1.5 to 2 years. New build projects are in early stages and will supplement revenue in the mid- to long-term.
Q:Does the target remain to exit this fiscal year at 3x leverage?
A:Anne Cybulsk confirmed that the goal is to return to the targeted leverage range by the end of the fiscal year, supported by healthy free cash flow generation.
Q:How will the Nuclear Energy segment's revenue trend over the next few years?
A:Ryan McLeod stated that the Nuclear Energy segment will grow, driven by healthy backlog and funnel activity in refurbishment, decommissioning, and new builds. However, he did not specify a percentage of revenue.
Q:When will the company cycle over large enterprise orders from last year?
A:Anne Cybulsk stated that they are executing on large orders booked in Q2 last year, which are in later stages. New work is being booked to fill the backlog as these projects are completed.
Q:What gives confidence in hitting the 15% working capital target this year?
A:Anne Cybulsk mentioned that milestone billings and collections on larger opportunities will drive improvement. Efforts to improve working capital efficiency across the business, including recently acquired businesses, support the target.
Q:Why does Life Sciences revenue seem slow, and is it related to government policy?
A:Ryan McLeod attributed the slower revenue to timing on project execution. He noted that exposure to publicly funded institutions is small, and initiatives like joint go-to-market approaches aim to offset funding challenges.
Q:What is the annual margin expansion target?
A:Anne Cybulsk stated that the company expects year-over-year margin expansion, aiming to exceed last year's adjusted EBITDA margin of 13.8%.
Q:Does the high single-digit revenue growth guidance include organic growth, M&A, and FX?
A:Anne Cybulsk confirmed that the guidance includes total revenue, with M&A benefits from the first half and FX impacts.
Q:What is the impact of oral GLP-1 applications on auto-injector demand?
A:Ryan McLeod stated that oral alternatives face challenges like nausea and absorption issues. Auto-injectors remain the most reliable and widely adopted delivery format for GLP-1 drugs, with oral formulations potentially complementing them in maintenance phases.
Q:What percentage of the Life Sciences backlog is related to GLP-1?
A:Ryan McLeod confirmed that GLP-1 remains approximately 20% of the Life Sciences backlog.
Q:Should SG&A grow slower than overall revenue growth?
A:Anne Cybulsk stated that the goal is to improve SG&A leverage as the top line grows, contributing to margin expansion.
Q:Review of Unclear Management Responses
A:Management avoided providing specific percentages or detailed timelines for certain questions, such as the exact growth percentage of the Nuclear Energy segment's revenue and the quarterly margin trajectory. Additionally, responses to questions about the impact of oral GLP-1 applications and SG&A growth were general and lacked detailed data or projections.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ABM Conference
ABM focus
ABM framework
ABM value
ATS Cybulsk
ATS Summit
ATS panel
ATS project
ATS provider
ATS set
ATS summary
ATS today
America win
Beverage end
CEO summer
Center Indianapolis
Competence Center
Conference improvement
Cybulsk Interim
Energy order
GLP diversification
GLP therapy
Illuminate Manufacturing
Indianapolis service
Interim Chief
Order
access
base
center
deployment
drug delivery
effort
inspection
investment
lab
leader
platform
portfolio
production
reactor build
refurbishment
strength
ATS Transcript
ATS Corporation (ATS:CA) Q4 2026 Earnings Call Transcript
Positive5-28
The earnings call summary and Q&A highlight strong backlogs across key sectors, positive revenue guidance, and strategic investments in growth areas. Despite some restructuring costs, the company is focused on margin expansion and capital efficiency. The Q&A reveals confidence in future growth, particularly in Life Sciences and nuclear segments, and potential M&A activities. The strategic plan and strong working capital management further support a positive outlook. Given the market cap, these factors suggest a stock price movement in the 2% to 8% range over the next two weeks.
ATS Corporation (ATS:CA) Q3 2026 Earnings Call Transcript
Unknown2-4
The earnings call presents a mixed picture. While there is optimism about growth in Life Sciences and nuclear segments, and a strong order backlog, the decrease in gross margin and increased SG&A expenses are concerns. The Q&A reveals cautious optimism but lacks specific guidance, which may cause uncertainty. Given the market cap of $3.18 billion, the stock is likely to have a muted reaction, resulting in a neutral sentiment.
ATS Corporation (ATS:CA) Q2 2026 Earnings Call Transcript
Positive11-5
The earnings call summary and Q&A indicate strong financial performance, with a solid order backlog and promising growth in segments like Life Sciences and Energy. Despite some uncertainties, management provided optimistic guidance, focusing on margin expansion and strategic initiatives. The stock is likely to experience a positive movement, considering the company's market cap and the absence of significant negative factors.
ATS Corporation (ATS) Q1 2026 Earnings Call Transcript
Positive8-7
The earnings call presented a strong backlog, positive integration of acquisitions, and favorable market conditions for automation. Management's optimistic guidance on margin improvements and leverage targets, along with strategic diversification efforts, indicate a positive outlook. The Q&A reinforced this sentiment, revealing minimal negative impact from external pressures and ongoing M&A activity. The market cap suggests a moderate reaction, leading to a 'Positive' stock price prediction over the next two weeks.
ATS Slides
ATS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
